Cancer Gene Therapy Market Report (2023 to 2031) - GlaxoSmithKline Inc., Altor Bioscience Inc., Bluebird bio-Inc., Abeona Therapeutics Inc. and GenVec
Growth Plus Reports
6 min read
Growth Plus Reports
Newark, New Castle, USA, July 02, 2023 (GLOBE NEWSWIRE) -- According to a recent study by Growth Plus Reports, the Global Cancer Gene Therapy Market was valued at US$ 1.64 billion in 2022 and is expected to register a revenue CAGR of 19.8% to reach US$ 8.33 billion by 2031 during the forecast period from 2023 to 2031. The research describes the most successful strategies, market trends, key drivers and opportunities, the competitive landscape, market size, statistic figures, revenue forecasts, and key investment areas.
Key Takeaways:
Advancements in gene therapy technologies are responsible for market revenue growth.
Modifying or manipulating genes under gene therapy are latest innovative therapy to treat cancer.
The growing investment and government initiatives are creating a range of novel treatment options.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Market Drivers: The significant market revenue in cancer gene therapy is due to increasing investment in gene therapy research and technological advancements. As a result, various potential gene treatments have been developed, which are expected to fuel the expansion of the cancer gene therapy market revenue. However, several factors, such as adverse immune response, toxicity, Safety concerns, and expense, may restrain the growth of the global cancer gene therapy market, especially in countries with limited healthcare budgets.
Market Segmentation: Growth plus reports have analyzed the global cancer gene therapy market from perspectives such as therapy type, indication, end-user, and region.
Therapy Type Segmentation: Based on therapy type, the global cancer gene therapy market has been segmented into gene-induced immunotherapy, gene transfer, and oncolytic virotherapy. Gene-induced immunotherapy accounts for the largest revenue share in the global market. The large revenue share can be attributed to rising cancer research aiming to strengthen the immune response to reduce cancer proliferation.
Oncolytic virotherapy is expected to grow at the fastest revenue CAGR during the forecast period. This revenue share is attributed to the favorable outcomes and the level of efficacy offered.
Indication Segmentation: Based on indication, the global cancer gene therapy market has been segmented into lung cancer, prostate cancer, breast cancer, pancreatic cancer, and others.
Breast cancer is the rapidly growing global cancer gene therapy market segment. This large revenue share is attributed to the high acceptance of gene therapy all over the world to treat breast cancer.
End-User Segmentation: Based on end-users, the global cancer gene therapy market has been segmented into academic & research institutes, biopharmaceutical companies, and others.
Biopharmaceutical companies account for the largest global cancer gene therapy market revenue share. This significant revenue share is attributed to the increasing global incidence of several malignancies owing to diverse inherited, environmental, and lifestyle risk factors and rising acceptance of elemental gene therapy choices by biopharmaceutical giants.
Regional Growth Dynamics: Based on region, the global cancer gene therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounts for the largest revenue share in the global cancer gene therapy market. The regional revenue is driven by factors including the rising incidence of cancer, the rising demand for cutting-edge cancer treatments, major market players, and the rising expenditures on R&D activities.
Competitive Landscape The prominent players operating in the global cancer gene therapy market are: -
Altor Bioscience Inc.
BioCancell Therapeutic Inc.
Bluebird bio-Inc.
GlaxoSmithKline Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Abeona Therapeutics Inc.
Asklepios BioPharmaceutical Inc.
GenVec
Introgen Therapeutics Inc.
The global cancer gene therapy market is relatively competitive due to late technologies, competitive players, mergers, and acquisitions. Furthermore, the market recognized partnerships, acquisitions, and various other types of collaboration as robust growth strategies, increasing the likelihood of revenue growth in the future.
Recent Development:
In March 2023, Abeona Therapeutics Inc.'s ophthalmology business announced three internally generated exploratory preclinical gene therapy product candidates.
In February 2023, Akamis Bio, a clinical-stage oncology business, announced an expansion of its current cooperation with the Parker Institute for Cancer Immunotherapy (PICI), including a clinical collaboration with the Cancer Research Institute (CRI) focused on pancreatic cancer medicines.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY THERAPY TYPE
Gene-Induced Immunotherapy
Gene Transfer
Oncolytic Virotherapy
GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY INDICATION
Lung Cancer
Prostate Cancer
Breast Cancer
Pancreatic Cancer
Others
GLOBAL CANCER GENE THERAPY MARKET - ANALYSIS & FORECAST, BY END-USER
High-Grade Neuroendocrine Neoplasms Market by Drug Class (Platinum Coordination Complexes, Somatostatin Analogues), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Postoperative Pain Medication Market by Drug Class (NSAIDS, Opioids), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Mast Cell Stabilizers Market by Type (Mastocytosis, Seasonal Allergic Rhinitis, and Perennial Allergic Conjunctivitis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Outlook and Forecast 2023-2031
COMT Inhibitors Market by Drugs (Entacapone, Tolcapone), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Neurofibromatosis Market by Type (NF1, NF2), Drug Class (Antihistamines, Antineoplastic Agents), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".
